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Abstract In this study we show that platelet-derived growth
factor (PDGF)-induced DNA binding as well as transcriptional
activation of Stat5b are markedly increased by inhibition of the
MAP (mitogen-activated protein) kinase kinase MEK. In
addition to the previously demonstrated tyrosine phosphoryla-
tion, we show that serine and threonine phosphorylation of
Stat5b is increased in response to PDGF stimulation. However,
inhibition of MEK had no effect on the phosphorylation level of
Stat5b or on the nuclear translocation of Stat5b. These
observations indicate that MEK is a negative modulator of
PDGF-induced Stat5b activation through a mechanism not
involving direct phosphorylation of Stat5b.
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1. Introduction
Platelet-derived growth factor (PDGF) is a potent growth
factor for mesenchymal cells. It is made up as dimers of two
related polypeptide chains, designated A and B, which are
assembled as homo- or heterodimers (PDGF-AA, PDGF-
BB and PDGF-AB). PDGF elicits its e¡ect by binding to
two related receptors, denoted K- and L-receptors. The bind-
ing of PDGF activates the intrinsic tyrosine kinase activity of
the receptors and induces autophosphorylation of speci¢c ty-
rosine residues which then allow for interactions with cyto-
plasmic proteins which transduce signals further into the cell
(reviewed in [1]).
Signal transducers and activators of transcription (Stat)
proteins were ¢rst discovered in conjunction with studies of
interferon signaling. Subsequently, seven members of the Stat
family have been identi¢ed, that mediate transcriptional reg-
ulation in response to a diverse group of cytokines and
growth factors (reviewed in [2]). Structurally, the Stat proteins
share a number of common features, including a DNA bind-
ing domain, an SH2 domain, and a putative SH3 domain.
Phosphorylation of a speci¢c tyrosine residue at the car-
boxy-terminal tail of the Stat proteins induces their dimeriza-
tion, nuclear translocation and subsequent binding to speci¢c
promoter sequences. In cytokine receptor signaling, this tyro-
sine phosphorylation is mediated by members of the Janus
kinase family (Jak) of tyrosine kinases [3]. In addition, tyro-
sine kinase receptors for PDGF, EGF and colony stimulation
factor-1 (CSF-1) can also activate the Stats through tyrosine
phosphorylation [4^7]. Thus, PDGF stimulation leads to ty-
rosine phosphorylation and DNAbinding activity of Stat1,
Stat3, Stat5 and Stat6 [4,8^10]. In contrast to signaling via
the cytokine receptors, PDGF- and EGF-mediated tyrosine
phosphorylation of Stats seems not to require Jak kinase ac-
tivity [11^13]. Whether the kinase activity of the receptor itself
or another kinase is involved in tyrosine phosphorylation of
Stats upon growth factor stimulation is currently not known.
In addition to the essential role of tyrosine phosphorylation
for Stat activation, serine phosphorylation of Stats has also
been implicated in regulation of their transcriptional activity
[14^16]. Thus, serine phosphorylation has been reported to be
critical for maximal transcriptional activation of Stat1K and
Stat3 in response to cytokines and growth factors [15].
Although the serine kinase(s) responsible for the phosphoryl-
ation of Stats have not been characterized, a proposed phos-
phorylation site for the MAP (mitogen-activated protein) ki-
nases Erk1 and Erk2, -Pro-X-Ser-Pro [17] is conserved among
Stat1, Stat3, and Stat4, suggesting a role for Erk in serine
phosphorylation of these proteins [15,16]. The observation
that Erk2 and Stat1 interact physically after stimulation
with K- or L-interferon also supports the notion that there is
a functional communication between these signaling mole-
cules when cells are activated [14]. However, Erk-independent
serine phosphorylation of Stat3 has also been reported [18,19].
Stat5 is also phosphorylated on serine residues after cytokine
stimulation. Whereas previous reports have indicated that Erk
does not phosphorylate Stat5b, it might contribute to phos-
phorylation of Stat5a in response to prolactin stimulation [20^
22].
The Ras/MAP kinase pathway plays an important role in
transmission of signals from the activated PDGF receptor.
Activation of Ras leads to the sequential activation of en-
zymes in the MAP kinase cascade, i.e. Raf-1, MEK and
Erk. The aim of this study was to determine the role of the
MAP kinase cascade in PDGF-mediated activation of Stat5.
2. Materials and methods
2.1. Cell culture
Porcine aortic endothelial (PAE) cells stably transfected with
PDGF L-receptor [23] were cultured in Ham’s F-12 medium (Gibco),
supplemented with 10% fetal calf serum (Gibco), 100 U/ml of peni-
cillin and 100 Wg/ml of streptomycin. NIH 3T3 cells stably expressing
wild-type MEK1 or catalytically inactive MEK1 (K97M), kindly pro-
vided by Natalie Ahn, Howard Hughes Medical Institute, Boulder,
CO, USA [24], NIH 3T3 cells and COS-1 cells were cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM; Gibco BRL), supple-
mented with 10% fetal calf serum (Gibco), 100 U/ml of penicillin
and 100 Wg/ml streptomycin.
2.2. Antisera and reagents
The rabbit antisera against Stat5b and Stat5a were purchased from
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Santa Cruz Biotechnology (Santa Cruz, CA, USA). The monoclonal
anti-phosphotyrosine antibody PY20, was from Transduction Labo-
ratories. The rabbit antiserum against Erk2 kinase (EET) was raised
against a C-terminal peptide (EETARFQPGYRS). The myelin basic
protein was purchased from Life Technologies-BRL. The MEK in-
hibitor PD98059 was purchased from Biomol Research Laboratories
(Plymouth Meeting, PA, USA) Cells were incubated with 30^100 WM
concentrations of the inhibitor at 37‡C for 1 h prior to stimulation
with PDGF; cells were then analyzed for Stat5 phosphorylation, nu-
clear translocation, DNAbinding and transcriptional activity, as de-
scribed below.
2.3. Immunoblotting
Serum-starved cells were stimulated with 100 ng/ml PDGF-BB for
0, 10 or 30 min at 37‡C. After washing with ice-cold phosphate bu¡-
ered saline (PBS), cells were lysed in a bu¡er containing 1% NP-40,
10% glycerol, 20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM phenyl-
methylsulfonyl £uoride (PMSF), 1% Trasylol, 100 WM Na3VO4. Im-
munoprecipitation and immunoblotting were performed as previously
described [25].
2.4. Analysis of PRE binding by immunoblotting
NIH 3T3 cells or PAE cells expressing PDGF L-receptor (108 cells)
were stimulated with 100 ng/ml PDGF-BB for 30 min at 37‡C, washed
and nuclear extracts prepared as described by [8]. The nuclear extracts
were diluted with 1 ml of electrophoretic mobility shift assay binding
bu¡er (12 mM HEPES pH 7.6, 8 mM KCl, 0.5 mM EDTA, 3.5%
glycerol) and incubated ¢rst for 1 h with agarose-linked streptavidin
(Sigma) to remove non-speci¢c material and then overnight with im-
mobilized oligonucleotide containing the Stat5 binding site of the
bovine L-casein promoter (PRE; 5P-GA TTT CTA GGA ATT
CAA-3P), obtained by incubating 40 Wl of agarose-linked streptavidin
with 0.2 Wg of double-stranded PRE oligonucleotide biotinylated at
the 5P end of the upper strand. After washing, agarose-bound material
was subjected to immunoblotting as described above.
2.5. Plasmids and cDNA transfections
The PDGF L-receptor [26] was cloned into the mammalian expres-
sion vector pcDNA3 (Invitrogen). The pXM-Stat5 plasmid [27] and
the pZZ1 constructs were kindly provided by Olli Silvennoinen (Uni-
versity of Tampere, Finland) and Bernd Groner (Institute for Exper-
imental Cancer Research, Freiburg, Germany). The pZZ1 construct
contains the L-casein promoter from 3344 to 31 in front of the
luciferase gene of the pLucDSS vector [28]. Transient transfections
were performed by the DEAE-dextran technique. Two Wg of pXM-
Stat5, L-receptor and pZZ1 cDNAs were used for transient transfec-
tions into COS-1 cells. In addition, 1.5 Wg of the plasmid pCH110,
encoding the L-galactosidase gene under the control of the SV40 pro-
moter (Pharmacia Biotech), were included in each transfection as an
internal control for the transfection e⁄ciency.
2.6. Luciferase and L-galactosidase assays
COS-1 cells were left untreated or were incubated with 30 WM
PD98059 for 1 h prior to stimulation with 100 ng/ml PDGF-BB for
5 h. Then L-galactosidase and luciferase activities were determined on
triplicate samples using the L-galactosidase assay system (Promega)
and luciferase assay system (Promega) as described by the manufac-
turer. Luciferase activities were corrected for the L-galactosidase val-
ues obtained in each experiment.
2.7. MAP kinase assay
Serum-starved cells were stimulated with 100 ng/ml PDGF-BB at
37‡C for 0, 5, 10 or 30 min. The cells were lysed and subjected to
MAP kinase assay as described previously [29], using myelin basic
protein (MBP) as a substrate.
2.8. In vivo [32P]orthophosphatelabeling of cells
Serum-starved cells were washed four times in phosphate-free
Ham’s F-12, containing 0.2% dialyzed FCS and 20 mM HEPES,
pH 7.2, and then incubated for 3 h at 37‡C in phosphate-free medium
containing 2 mCi/ml [32P]orthophosphate and 50 WM Na3VO4. Cells
were stimulated for 10 min at 37‡C with 100 ng/ml PDGF-BB, washed
three times with ice-cold PBS before lysis in 1% NP-40, 10% glycerol,
20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM PMSF, 1% Trasylol,
100 WM Na3VO4. Insoluble material was removed by centrifugation at
14 000Ug for 10 min at 4‡C. The cleared lysates were immunoprecip-
itated with Stat5 antiserum and then subjected to SDS-polyacrylamide
electrophoresis using 7% polyacrylamide gels. The separated proteins
were transferred to a PVDF membrane and exposed on X-ray ¢lm or
on a Bio-Imager screen (Fuji). The phosphorylated Stat5 was cut out
and processed for trypsin cleavage and two-dimensional phosphor-
amino acid analysis as described previously [30].
3. Results
3.1. Increased DNA binding activity of Stat5 by inhibition of
MEK
The MAP kinase pathway plays an important role in the
regulation of cell growth and di¡erentiation. One common
signaling pathway leading to activation of the MAP kinases
Fig. 1. Increased DNA binding activity of Stat5b by inhibition of
MEK. A: NIH 3T3 cells were left untreated or were incubated with
30 WM PD98059 for 1 h prior to stimulation with PDGF-BB for 30
min at 37‡C; nuclear extracts were then prepared. PREbinding com-
plexes were isolated from the nuclear extracts using the immobilized
PRE probe. DNA-bound proteins were analyzed by immunoblotting
with Stat5 antiserum. B: PAE cells expressing PDGF L-receptor
were incubated with 30 or 60 WM PD98059 for 1 h prior to stimula-
tion with PDGF-BB. PRE binding activity was then analyzed as de-
scribed in A. C: NIH 3T3 cells stably expressing wild-type (WT) or
catalytically inactive (K97M) MEK1 were stimulated with PDGF-
BB for 30 min at 37‡C; nuclear extracts were then prepared and
the DNA-bound proteins analyzed as described in A. The position
of Stat5 is indicated on the right.
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Erk1 and Erk2 is dependent on the upstream e¡ectors, Ras,
Raf-1 and MAP kinase kinases (MEK1 and MEK2). Since
Erks have been suggested to regulate activation of Stat1 and
Stat3 in cytokine signaling, we were interested in knowing
whether members of the MAP kinase cascade a¡ected
PDGF-mediated activation of Stat5. We initially estimated
whether the highly speci¢c MEK inhibitor PD98059 [31,32]
had any e¡ect on the DNA binding activity of Stat5 after
PDGF stimulation. For this purpose, NIH3T3 cells were in-
cubated with 30 WM PD98059 or vehicle for 1 h at 37‡C and
then stimulated or not with PDGF-BB for 30 min at 37‡C.
Nuclear extracts were prepared and equal amount of protein
incubated with biotinylated PRE probe (derived from the
Stat5 binding site on the L-casein promoter), immobilized
on agarose-linked streptavidin. Bound proteins were then
eluted and analyzed by SDS-PAGE, followed by immunoblot-
ting with Stat5b speci¢c antiserum. As shown in Fig. 1A,
PDGF stimulation led to binding of Stat5b to the PRE probe,
in agreement with previous observations [8]. Interestingly,
DNAbinding of Stat5b was markedly enhanced in cells
treated with PD98059. The ¢lter was also immunoblotted
with antiserum against Stat5a, but no DNA-bound Stat5a
was detected by this assay (data not shown). We also per-
formed a similar experiment using PAE cells ectopically ex-
pressing the wild-type PDGF L-receptor. Cells were incubated
with 30 or 60 WM PD98059 prior to stimulation with PDGF,
and analyzed as described above. In these cells, weak DNA-
binding of Stat5b was detected after stimulation with PDGF-
BB, whereas pretreatment with the MEK inhibitor led to a
markedly increased DNA-binding of Stat5b (Fig. 1B).
To con¢rm that PDGF-mediated Erk activation was inhib-
ited in the presence of PD98059, serum-starved NIH3T3 cells
were treated with 100 ng/ml PDGF for 0, 5, 10 or 30 min at
37‡C. The cells were lysed, and the Erk2 protein immunopre-
cipitated and subjected to a kinase reaction with MBP as an
exogenous substrate. Incorporation of 32Pradioactivity into
MBP, as analyzed by SDS-PAGE followed by autoradiogra-
phy, was taken as a measure of Erk activity. PDGF stimula-
tion of NIH3T3 cells resulted in an extensive activation of
Erk2, with a 12-fold increase in phosphorylation of MBP,
after 5 min of stimulation. However, in the presence of the
MEK inhibitor PD98059, the Erk activation in response to
PDGF stimulation was only about four-fold (Fig. 2).
In order to further investigate the potential role of MEK in
inhibition of PDGF-activated Stat5, we estimated DNA bind-
ing of Stat5 in NIH 3T3 cells, stably expressing wild-type
MEK1 or catalytically inactive MEK1 acting in a dominant
negative manner [24]. The cells were stimulated or not with
PDGF-BB for 30 min at 37‡C, nuclear extracts prepared and
equal amount of protein extract incubated with biotinylated
PRE probe, immobilized on agarose-linked streptavidin.
Bound proteins were then analyzed by SDS-PAGE, followed
by immunoblotting with Stat5b. As shown in Fig. 1C, Stat5b
bound the PREprobe much more e⁄ciently in NIH 3T3 cells
expressing catalytically inactive MEK1, as compared to cells
expressing wild-type MEK1. Control experiments in which
cellular lysates were immunoblotted with antiserum recogniz-
ing phosphorylated Erk2 revealed that Erk2 was not phos-
phorylated after PDGF stimulation in cells expressing domi-
nant negative MEK1, in contrast to cells expressing wild-type
MEK1 (data not shown).
Taken together, these observations indicated that MEK, or
Fig. 2. E¡ect of PD98059 on Erk activation. NIH3T3 cells were
stimulated with 100 ng/ml PDGF-BB for 30 min on ice followed by
0, 5, 10 or 30 min at 37‡C, lysed and immunoprecipitated with anti-
serum against Erk2. The immunoprecipitated samples were subjected
to in vitro kinase assay in the presence of the exogenous substrate
MBP, followed by SDS-PAGE and autoradiography. The histogram
in the lower part of the ¢gure shows the relative intensities of the
32P-containing MBP bands in the di¡erent lanes, quanti¢ed on a
Bio-Imaging analyzer.
Fig. 3. Increased PDGF-induced L-casein promoter activity in the
presence of MEK inhibitor. COS cells transfected with L-casein pro-
moter luciferase construct (pZZ1), Stat5, and L-receptor (lanes 5, 6,
7 and 8) were incubated (black bars) or not (gray bars) with 30 WM
PD98059 for 1 h prior to stimulation with 100 ng/ml PDGF-BB for
5 h. Cell extracts were prepared and luciferase activity determined
in triplicate samples. All transfections included plasmid pCH110
and L-galactosidase assays were used as a control for transfection
e⁄ciency. Luciferase activities were normalized to the L-galactosi-
dase activities.
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its downstream e¡ectors, are negative regulators of Stat5b
DNA binding activity upon PDGF stimulation.
3.2. Increased Stat5 transcriptional activity in the presence of
MEK inhibitor
We next examined the e¡ect of MEK inhibition on the
transcriptional activity of Stat5. PDGF L-receptor, Stat5
and the Stat5-responsive L-casein promoter-luciferase con-
struct were coexpressed in COS cells and the cells stimulated
with 100 ng/ml PDGF-BB for 5 h in the presence or absence
of 30 WM PD98059. The transcriptional activation of the L-
casein promoter-luciferase reporter gene upon stimulation
with PDGF-BB was then measured. As shown in Fig. 3,
PDGF-stimulated luciferase activity was almost twice as
high in cells treated with PD98059. Thus, the transcriptional
activity of Stat5 appears to be negatively modulated by MEK
in PDGF-stimulated cells.
3.3. Tyrosine phosphorylation of Stat5b and the PDGF
L-receptor is not a¡ected by treatment with MEK inhibitor
Tyrosine phosphorylation of Stats is critical for their dimer-
ization, nuclear translocation and subsequent transcriptional
activity. Therefore, we examined whether tyrosine phospho-
rylation of Stat5 was modulated by inhibition of MEK. Se-
rum-starved NIH 3T3 cells were incubated or not with
PD98059 prior to stimulation with PDGF for 0, 10 or 30
min at 37‡C. Cells were lysed and immunoprecipitated with
Stat5b antiserum and the immunoprecipitates analyzed by
SDS-PAGE followed by immunoblotting with phosphotyro-
sine antibodies (PY20). As shown in Fig. 4A, tyrosine phos-
phorylation of Stat5b was virtually una¡ected by the presence
of 30 WM PD98059. The amount of Stat5 was similar in all
lanes as revealed by immunoblotting of the same ¢lter with
Stat5b antiserum (Fig. 4B). As shown in Fig. 4B, this anti-
serum crossreacted with Stat5a, however, Stat5a was not rec-
ognized by phosphotyrosine antibodies by this approach. In
order to con¢rm the speci¢city of PD98059, we investigated
whether phosphorylation of PDGF L-receptor was a¡ected by
the inhibitor. Therefore cell lysate from NIH3T3 cells stimu-
lated with PDGF were separated by SDS-PAGE, followed by
immunoblotting with phosphotyrosine antibodies. As shown
in Fig. 4C, tyrosine phosphorylation of the PDGF L-receptor
was not a¡ected by pretreatment with the MEK inhibitor, in
agreement with previous reports [32]. By a similar approach
we also found that tyrosine phosphorylation of PLC-Q was
not a¡ected by PD98059 (data not shown). These data indi-
cate that the increased DNAbinding activity of Stat5b upon
MEK inhibition is not due to a change in tyrosine phospho-
rylation of Stat5b.
3.4. Serine/threonine phosphorylation of Stat5 is not reduced by
MEK inhibition
To further analyze the phosphorylation level of Stat5b in
the presence or absence of PD98059, serum-starved NIH 3T3
cells, treated or not with PD98059, were labeled for 3 h with
[32P]orthophosphate and then stimulated or not with PDGF
for 10 min at 37‡C. After cells lysis, Stat5b was immunopre-
cipitated from the lysate and analyzed by SDS-PAGE. The
phosphorylated Stat5b was visualized by autoradiography,
transferred to a PVDF membrane, and analyzed by phosphor-
amino acid analysis. In PDGF-stimulated cells, there was
about two-fold induction of serine/threonine as well as tyro-
sine phosphorylation of Stat5b; treatment with the MEK in-
hibitor did not lead to a decrease in PDGF-stimulated or
background phosphorylation of Stat5b; actually, slight in-
creases were noticed (Fig. 5). The observation that incubation
Fig. 4. Tyrosine phosphorylation of Stat5 in PDGF-stimulated cells
in the absence or presence of PD98059. NIH 3T3 cells were incu-
bated or not with 30 WM PD98059 for 1 h at 37‡C and then stimu-
lated or not with 100 ng/ml PDGF-BB for 0, 10 or 30 min at 37‡C.
Cells were lysed and subjected to precipitation with antiserum
against Stat5b followed by SDS-PAGE and immunoblotting with
PY20 (A), or antiserum against Stat5b (B). In (C), cell lysates from
NIH 3T3 cells, treated or not with PD98059 and stimulated with
PDGF-BB for 0, 10 or 30 min at 37‡C, were separated by SDS-
PAGE and immunoblotted with PY20. The positions of Stat5b
(closed arrowhead), Stat5a (open arrowhead) and the PDGF L-re-
ceptor (arrow) are indicated.
Fig. 5. Phosphorylation of Stat5 in the presence or absence of
MEK inhibitor. A: Serum-starved NIH 3T3 cells were incubated
with 30 WM PD98059 or vehicle for 1 h and then labeled in vivo
with 2 mCi/ml [32P]orthophosphate. Cells were left unstimulated or
stimulated with 100 ng/ml PDGF for 10 min at 37‡C, lysed and im-
munoprecipitated with antiserum against Stat5b. The immunopreci-
pitates were analyzed by SDS-PAGE and electrotransferred to a
PVDF membrane and analyzed by autoradiography. B: A histo-
gram showing the relative intensities of the [32P]orthophosphate-con-
taining phosphoserine (pSer), phosphothreonine (pThr), phosphotyr-
osine (pTyr), in the absence (black bars) or presence (hatched bars)
of 30 WM PD98059, quanti¢ed on a Bio-Imaging analyzer.
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with the MEK inhibitor did not result in a decreased serine/
threonine phosphorylation of Stat5b, suggests that MEK or
Erk do not phosphorylate Stat5b directly after PDGF stim-
ulation.
3.5. Nuclear translocation of Stat5 is not a¡ected by treatment
with MEK inhibitor
Tyrosine phosphorylation of Stat5 leads to homo- or het-
erodimerization of Stat5 subunits, followed by translocation
to the nucleus. We therefore estimated whether the transloca-
tion of Stat5 was a¡ected by the MEK inhibitor. For that
purpose, cytoplasmic and nuclear extracts were prepared
and equal amounts of nuclear extracts subjected to immuno-
precipitation with Stat5b antiserum, followed by SDS-PAGE
analysis and immunoblotting. As shown in Fig. 6A, a similar
amount of tyrosine phosphorylated Stat5b was detected in the
nuclear extract after PDGF-stimulation in cells treated or not
with MEK inhibitor. Immunoblotting with Stat5b antiserum
revealed that also the amount of Stat5b in the nucleus was
similar in cells treated or not with MEK inhibitor (Fig. 6B).
Thus, the induced DNA binding was not due to changes in
nuclear translocation of Stat5b. In contrast to the case for
Stat5b, tyrosine phosphorylated Stat5a was not detected in
the nucleus after PDGF stimulation (data not shown).
4. Discussion
In this study we have determined the e¡ect of MEK inhib-
ition on Stat5 activation in PDGF-stimulated cells. We show
that treatment of cells with the MEK inhibitor PD98059 leads
to an increased DNA binding and transcriptional activity of
Stat5b. Moreover, DNA binding of Stat5b upon PDGF stim-
ulation was markedly increased in cells expressing catalytically
inactive MEK1 as compared to cells expressing wild-type
MEK1. These data suggest that MEK or its downstream ef-
fectors Erks are negative regulators of Stat5b after PDGF
stimulation. Interestingly, it has been shown that the DNA
binding activity of Stat5 and the transcription of L-casein gene
in response to lactogenic hormones are impaired in mammary
epithelial cells transformed by the Ha-ras and the v-raf onco-
genes [33]. These observations are in line with our results
showing increased activation of Stat5b by inhibition of MEK.
The molecular mechanism involved in the modulation of
PDGF-stimulation of Stat5b by MEK, remains to be eluci-
dated. Stat5 has been shown to be phosphorylated on serine
residues upon cytokine stimulation; Ser-730 was recently
shown to be the major phosphorylation site in Stat5b, and
Ser-725 and Ser-780 have been suggested as phosphorylation
sites in Stat5a [21,22]. Whereas serine phosphorylation of
Stat5b was not essential for its transcriptional activity in re-
sponse to stimulation by growth hormone and prolactin
[22,34], it appeared to be important in response to IL-2 stim-
ulation [20]. In our study, phosphoramino acid analysis of
Stat5b immunoprecipitated from [32P]orthophosphate-labeled
cells revealed that phosphorylation of Stat5b on serine and
threonine residues increased upon stimulation with PDGF.
However, PDGF-induced serine/threonine phosphorylation
of Stat5b was not reduced in the presence of PD98059, sug-
gesting that Erk does not phosphorylate Stat5b. Serine phos-
phorylation of Stat5b has previously been proposed to be
responsible for its electrophoretic mobility shift upon stimu-
lation [20,34]. As shown in Figs. 4B and 6B, the electropho-
retic mobility shift of Stat5b was not a¡ected by the MEK
inhibitor, which further supports the notion that serine phos-
phorylation of Stat5b was not impaired. Our results are in
agreement with previous studies showing that Erk is not re-
quired for transcriptional activation of Stat5 in response to
IL-2 and prolactin stimulation [20,35,36].
Since serine/threonine phosphorylation of Stat5b was not
a¡ected by PD98059, the e¡ect of MEK on Stat5b activation
appears to be indirect. Increased activation of Stat5 was no-
ticed after 1 h of incubation with the MEK inhibitor, suggest-
ing that the induction of gene transcription was not required.
Furthermore, translocation of Stat5b into the nucleus was not
a¡ected upon MEK inhibition, suggesting that MEK modu-
lates Stat5b activity in the nucleus, e.g. by a¡ecting interac-
tions with other transcription factor(s). Stats have been shown
to act together with other classes of transcription factors, e.g.
the glucocorticoid receptor together with which Stat5b stim-
ulates, in a synergistic manner, the L-casein promoter [37,38].
The results presented in the present communication illus-
trates one mechanism for modulation of Stat activation. Sev-
eral other such mechanisms have recently been proposed, in-
cluding dephosphorylation of the regulatory C-terminal
tyrosine residue of Stats which results in loss of dimerization
and inactivation of DNA binding [39], proteolytic degrada-
tion, negative regulation by cytokine-inducible proteins of the
SOCS/JAB/SSI family [40^42], and through inhibition by the
PIAS (protein inhibitor of activated Stats) family of proteins,
which act as negative regulators of Stat DNA binding activity
[43,44].
Stat5a and Stat5b are closely related proteins, encoded by
separate genes. In our study we saw that both Stat5b (Fig. 4)
and Stat5a (data not shown) were tyrosine phosphorylated in
response to PDGF stimulation. However, only tyrosine phos-
phorylated Stat5b, and not Stat5a, was detected in the nucleus
upon PDGF-stimulation of NIH 3T3 cells and only Stat5b
was detected in complex with PRE probe in the DNA-binding
assays. Studies on Stat5 knockout mice have shown that
Stat5a and Stat5b have separate physiological functions.
Thus, Stat5a has been shown to be important for mammary
gland development and lactogenesis [45], whereas Stat5b is
Fig. 6. Nuclear translocation of Stat5b is not a¡ected by MEK in-
hibitor. NIH 3T3 cels were incubated or not with 30 WM PD98059
for 1 h at 37‡C, and then stimulated or not with 100 ng/ml PDGF-
BB for 30 min on ice, followed by 10 or 30 min at 37‡C. Nuclear
extracts were prepared and Stat5b immunoprecipitated from the ly-
sate. The precipitate was analyzed by SDS-PAGE and transfered to
¢lter, followed by immunoblotting with PY20 and Stat5b antiserum.
The position of Stat5b (closed arrowhead) is indicated on the right.
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involved in sexual dimorphism of body growth rates and liver
gene expression [46]. The e¡ects of disruption of the Stat5b
gene on body fat deposition were marked with signi¢cantly
less adipose tissue both in Stat5b3=3 females and males com-
pared with wild-type mice. Furthermore, the expression of
Stat5b has been shown to be tightly correlated with the adi-
pocyte phenotype of 3T3-L1 cells, with a markedly elevated
expression in adipocytes as compared with their ¢broblast
precursors [47]. Previous studies have indicated that PDGF,
together with insulin, a¡ects adipose di¡erentiation of 3T3-L1
preadipocytes [48,49]. Therefore, it is possible that PDGF-
stimulated Stat5b has a role in this di¡erentiation process.
It is noteworthy that previous studies have indicated that
MAP kinase activity a¡ects adipocytic di¡erentiation of
3T3-L1 cells [50,51]; it is an interesting possibility, which re-
mains to be elucidated, that the modulation of Stat5b activa-
tion by MEK might play a role in di¡erentiation of preadi-
pocytes.
PDGF activates Stat5b by promoting its phosphorylation
on tyrosine residues [8]. At the same time PDGF induces
activation of the MAP kinase cascade, which leads to inhib-
ition of Stat5b activity as suggested by the data shown in the
present study. This is thus yet another example that stimula-
tory and inhibitory pathways for various responses, are initi-
ated in parallel at the activated PDGF receptor (reviewed in
[1]). We noticed that treatment with PD98059 markedly re-
duced PDGF-mediated DNA synthesis (data not shown) in
agreement with previous observations [52]. Thus, the DNA
binding activity of Stat5b increased simultaneously as the
PDGF-induced mitogenicity decreased; however, it remains
to be determined whether Stat5b directly modulates PDGF-
induced mitogenicity. An important issue for future studies is
to clarify the mechanism of induction of Stat5b activity by
PDGF and to determine the functional role of Stat5b in
PDGF signaling.
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